Water Cooler Chat Session: Australia: Bridge to Asia-Pacific Clinical Trials | Recorded November 12, 2020

Asia Pacific is a growing destination for conducting cost-effective clinical trials – between 2007 and 2018 trials in Asia constituted around 28.5% of all registered clinical trials globally – with patient recruitment increasing faster than both Europe and North America. 

The key to any successful clinical trial is having a robust, responsive and efficient supply chain process which enables consistent global supply. Australia is one of the most mature markets in the Asia-Pacific region for clinical trials, with the Australia drug sector investing more than AUD$1 billion annually into research and development and outsourcing services. 

Well-regarded internationally for its world-class infrastructure Australia has a number of advantages that make it a destination of choice. On November 10th & 12th our experts, KoSung Lee, Andrew Castles and Rich Nelson, discussed why you should consider Australia as your Bridge to conducting successful Trials in Asia. 

When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?

Your bridge between life-changing therapies and patients